scholarly journals Primary Small-Cell Carcinoma of the Hard Palate: An Extremely Rare Occasion

2021 ◽  
Vol In Press (In Press) ◽  
Author(s):  
Abtin Doroudinia ◽  
Siamak Salahi ◽  
Atosa Dorudinia ◽  
Payam Mehrian ◽  
Reza Naseri ◽  
...  
Keyword(s):  
Cell Carcinoma ◽  
Small Cell Carcinoma ◽  
Hard Palate ◽  
Neck Region ◽  
Small Cell ◽  
Small Cells ◽  
Divergent Differentiation ◽  
Organ Specific ◽  
Rare Occasion ◽  
Extra Pulmonary

: Most primary small cells carcinoma develop from the lung, and extra-pulmonary small cell carcinoma accounts for less than 5% of all small cell carcinoma cases. In the head and neck region, the most common sites are the larynx and salivary glands; however primary involvement of the palate is extremely rare. The extra-pulmonary small cell carcinoma is similar to its pulmonary counterpart regarding morphology, immunohistochemistry, and electron microscopy features and derives from pluripotential stem cells that develop neuroendocrine features. There is growing evidence regarding the ability of extra-pulmonary small cell carcinoma to arise from pluripotent basilar cells capable of divergent differentiation with the consequence of arising neuroendocrine phenotype as a trans-differentiation phenomenon in the progression of an organ-specific carcinoma. The differentiation between primary and metastatic extra-pulmonary small cell carcinoma is challenging. There is also no standard guideline for treatment as it is a rare occasion, and there is no consensus between radiation oncologists and cancer surgeons about the best treatment strategy. In this study, a very rare case of hard palate small cell carcinoma with neuroendocrine pathology features is presented. To our best of knowledge, this is the third case report of extra-pulmonary small cell carcinoma involving the palate in the literature review. Knowing the clinical presentation and pathology characteristics of such rare tumor in addition to follow-up outcome can be highly useful to establish a reliable guideline for hard palate small cell carcinoma management.

Expression of C-flanking peptide of human pro-bombesin in pulmonary and extra-pulmonary small cell carcinoma

1986 ◽  
Vol 15 (2) ◽  
pp. 180 ◽  
Author(s):  
Q. Hamid ◽  
D.R. Springall ◽  
M.A. Ghatei ◽  
B.A. Fountain ◽  
B. Addis ◽  
...  
Keyword(s):  
Cell Carcinoma ◽  
Small Cell Carcinoma ◽  
Small Cell ◽  
Extra Pulmonary

Retrospective review of extra-pulmonary small cell carcinoma at King Chulalongkorn Memorial Hospital cases during 1998-2005

2010 ◽  
Vol 6 (2) ◽  
pp. 111-115 ◽  
Author(s):  
Thep CHALERMCHAI ◽  
Harit SUWANRUSME ◽  
Poonchavis CHANTRANUWAT ◽  
Narin VORAVUD ◽  
Virote SRIURANPONG
Keyword(s):  
Cell Carcinoma ◽  
Small Cell Carcinoma ◽  
Retrospective Review ◽  
Small Cell ◽  
Memorial Hospital ◽  
Extra Pulmonary

Neuroendocrine Carcinomas of the Upper Airways: A Small Case Series with Histopathological Considerations

2007 ◽  
Vol 93 (5) ◽  
pp. 499-503 ◽  
Author(s):  
Marco Capelli ◽  
Giulia Bertino ◽  
Patrizia Morbini ◽  
Chiara Villa ◽  
Stefano Zorzi ◽  
...  
Keyword(s):  
Cell Carcinoma ◽  
Head And Neck ◽  
Small Cell Carcinoma ◽  
Radical Surgery ◽  
Neck Region ◽  
Small Cell ◽  
Upper Airways ◽  
Head And Neck Region ◽  
Poorly Differentiated ◽  
Neuroendocrine Carcinomas

Neuroendocrine carcinomas are rare tumors. In the head and neck region they are most common in the larynx, where they represent 0.5-1% of epithelial cancers. Diagnosis requires the recognition of the typical neuroendocrine architecture and morphology and the immunohistochemical confirmation of neuroendocrine differentiation. In the 1991 WHO classification laryngeal neuroendocrine carcinomas have been divided into carcinoids, atypical carcinoids, small cell carcinomas and paragangliomas. Atypical carcinoids in the head and neck region usually show an aggressive behavior analogous to poorly differentiated carcinomas, and are resistant to chemo- and radiotherapy. For this reason, it was recently proposed to change their designation to “moderately differentiated neuroendocrine carcinomas”. We present the clinical and histopathological features of 2 moderately differentiated neuroendocrine carcinomas of the larynx, one large cell poorly differentiated neuroendocrine carcinoma of the oropharynx, and one small cell carcinoma of the minor salivary glands of the tongue. The patient with small cell carcinoma was free from disease 26 months after radical surgery, while the other patients showed liver, lung and bone metastases 18, 26 and 24 months after the diagnosis despite radical surgery or concomitant intra-arterial chemotherapy and radiotherapy.

scholarly journals Optimal Postoperative Treatment for Composite Laryngeal Small Cell Carcinoma

2013 ◽  
Vol 2013 ◽  
pp. 1-3
Author(s):  
Koji Ebisumoto ◽  
Akihiro Sakai ◽  
Kenji Okami ◽  
Ryousuke Sugimoto ◽  
Kosuke Saito ◽  
...  
Keyword(s):  
Adjuvant Chemotherapy ◽  
Cell Carcinoma ◽  
Small Cell Carcinoma ◽  
Treatment Strategies ◽  
Neck Region ◽  
Small Cell ◽  
Postoperative Treatment ◽  
Pathological Examination ◽  
Tumor Biopsy ◽  
Head And Neck Region

Small cell carcinoma (SmCC) most commonly occurs in the lung and rarely arises from the head and neck region. Further, composite SmCC is extremely rare. Therefore, no postoperative treatment strategy has been established. We report a 59-year-old male patient referred to our outpatient clinic for further examination and treatment of a laryngeal tumor. Biopsy from the tumor revealed squamous cell carcinoma (SCC). The preoperative diagnosis was supraglottic SCC (T3N2bM0), and total laryngectomy and bilateral neck dissection were performed. Pathological examination revealed 2 individual cancer components: SmCC and SCC. Postoperative chemoradiotherapy (2 courses of cisplatin (CDDP) and etoposide (VP-16)) was indicated. Following the postoperative chemoradiotherapy, 2 courses of adjuvant chemotherapy were administered. The patient is currently alive with no evidence of disease at 36 months following the completion of therapy. Postoperative chemoradiotherapy and adjuvant chemotherapy are optimal treatment strategies for laryngeal composite SmCC.

Esophagus: A Rare Site for Extra Pulmonary Small Cell Carcinoma

2016 ◽  
Vol 111 ◽  
pp. S741 ◽  
Author(s):  
Nayana George ◽  
Saad Khan ◽  
Saranya Addepally ◽  
Mohit Girotra ◽  
Benjamin Tharian
Keyword(s):  
Cell Carcinoma ◽  
Small Cell Carcinoma ◽  
Small Cell ◽  
Rare Site ◽  
Extra Pulmonary

Limited disease of extra-pulmonary small cell carcinoma

2012 ◽  
Vol 188 (3) ◽  
pp. 269-273 ◽  
Author(s):  
A.C. Müller ◽  
C. Gani ◽  
M. Weinmann ◽  
F. Mayer ◽  
B. Sipos ◽  
...  
Keyword(s):  
Cell Carcinoma ◽  
Small Cell Carcinoma ◽  
Small Cell ◽  
Limited Disease ◽  
Extra Pulmonary

scholarly journals Nonhematopoietic tumor cells express functional GM-CSF receptors

Blood ◽  
1989 ◽  
Vol 73 (4) ◽  
pp. 1033-1037 ◽  
Author(s):  
GC Baldwin ◽  
JC Gasson ◽  
SE Kaufman ◽  
SG Quan ◽  
RE Williams ◽  
...  
Keyword(s):  
Cell Carcinoma ◽  
Tumor Cells ◽  
Small Cell Carcinoma ◽  
Biological Activities ◽  
Small Cell ◽  
Small Cells ◽  
Receptor Protein ◽  
Acid Decarboxylase ◽  
African Green Monkey Kidney ◽  
Gm Csf

Human granulocyte-macrophage colony-stimulating factor (GM-CSF) stimulates the colony growth of myeloid progenitors in semisolid media, and enhances the function of mature effector cells, including neutrophils, monocytes, and eosinophils. Small cell carcinoma lines (SCCL) have properties of amine precursor uptake and decarboxylation (APUD) cells and express high levels of the enzyme, L-aromatic amino acid decarboxylase. We looked for possible expression of GM-CSF receptors on nonhematopoietic cells and found specific high-affinity binding of human GM-CSF to SCCL and to the SV40-transformed African green monkey kidney cell line, COS. The small cell carcinoma lines responded to GM-CSF with enhanced proliferation, and both small cells and COS cells were found to express authentic 84,000 dalton GM-CSF receptor protein. These findings indicate that nonhematopoietic cells can bind and respond to GM-CSF, suggesting additional biological activities as well as the possibility of tumor responses when GM-CSF is used therapeutically in humans. Since preliminary clinical trials using CSFs as adjunctive treatment in patients with solid tumors are underway, it will be important to consider the possible responsiveness of nonhematopoietic tumor cells to CSFs.

Sign in / Sign up

Export Citation Format

Share Document